|
Session 142
Poster Abstracts
Viral Rebound and Emergence of Drug Resistance
Monday, 1-4 pm
Room: Hall B |
| 888 |
RT-SHIV Subpopulation Dynamics before and during the Course of Antiviral Therapy
Wei Shao*1, M Kearney2, F Maldarelli2, J Mellors3, R Stephens1, J Lifson4, V KewalRamani2, Z Ambrose2, J Coffin5, and S Palmer2
1Advanced Biomed Computing Ctr, SAIC-Frederick, MD, US; 2HIV Drug Resistance Prgm NCI-Frederick, MD, US; 3Univ of Pittsburgh, PA, US; 4SIAC-Frederick, MD, US; and 5Tufts Univ, Boston, MA, US |
| 889 |
Differences in the Dynamics of Viral Rebound and Evolution of Resistance between CBV/NVP and CBV/ABC Uncovered in the Absence of Viral Load Monitoring in Real Time: NORA Substudy of the DART Trial
Nicaise Ndembi*1, D Pillay2, R Goodall3, A McCormick2, A Burke3, F Lyagoba1, P Munderi1, P Katundu4, S Tugume4, P Kaleebu1, and on behalf of the DART Virology
1Med Res Council/Uganda Virus Res Inst, Entebbe; 2Ctr for Virolgy, Univ Coll London, UK; 3Med Res Council Clinical Trials Unit, London, UK; and 4Joint Clin Res Ctr, Kampala, Uganda |
| 890 |
Absence of Protease Resistance with Virologic Rebound by Single Genome Sequencing on Atazanavir/Ritonavir as Simplified Maintenance Therapy: ACTG 5201
John McKinnon*1, T Wilkin2, S Swindells3, G DiRienzo4, C Fletcher5, D Margolis6, G Thal7, B Bastow8, K Droll4, J Mellors1, and the A5201 Study Group
1Univ of Pittsburgh, PA, US; 2Weill Med Coll of Cornell Univ, New York, NY, US; 3Univ of Nebraska Med Ctr, Omaha, US; 4Harvard Sch of Publ Hlth, Boston, MA, US; 5Univ of Colorado Hlth Sci Ctr, Denver, US; 6Univ of North Carolina at Chapel Hill, US; 7Bristol-Myers Squibb, Plainsboro, NJ, US; and 8ACTG Operations Ctr, Silver Spring, MD, US |
|
